Patients with multiple sclerosis treated with natalizumab may rarely develop progressive multifocal leukoencephalopathy (PML), a serious and often fatal disease caused by infection with JC virus. The ...
Patients with multiple sclerosis (MS) should be evaluated before, and regularly during, treatment with fingolimod (Gilenya, Novartis) to identify signs and symptoms possibly linked to progressive ...
Please provide your email address to receive an email when new articles are posted on . Researchers performed genetic analyses of 336 cases of those with PML, 94 of whom were patients with MS. Four ...
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating ...
The FDA has approved the first biosimilar to treat multiple sclerosis, Sandoz's injection treatment natalizumab-sztn (Tyruko). Sandoz's injection treatment natalizumab-sztn (Tyruko) has been approved ...
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials ...
Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results